Our Science

Publications & Presentations

Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

• Obexelimab, a B Cell Inhibitor, in IgG4-Related Disease: Results From the Phase 3 INDIGO Trial

  European Alliance of Associations for Rheumatology (EULAR) 2026 Congress
  June 2, 2026

• Obexelimab for the Treatment of IgG4-Related Disease

  New England Journal of Medicine
  June 2, 2026